The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | MUK Seven biomarker trial: prognostic molecular stratification in R/R MM
Martin Kaiser, MD, Royal Marsden NHS Foundation Trust, London, UK, outlines the results of the MUK Seven trial (NCT02406222), a study designed to investigate whether the addition of cyclophosphamide to pomalidomide and dexamethasone improves progression-free survival in patients with relapsed/refractory multiple myeloma (RRMM) compared to pomalidomide and dexamethasone alone. Additionally, a secondary aim was to explore and validate biomarkers for treatment optimization in RRMM. Results demonstrate that validated molecular markers predict treatment outcomes in RRMM, opening the potential for treatment stratification. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
